Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 227,337 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $18.38, for a total transaction of $4,178,454.06. Following the completion of the sale, the director owned 8,511 shares of the company's stock, valued at approximately $156,432.18. This represents a 96.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dyne Therapeutics Stock Performance
Shares of DYN stock opened at $17.55 on Friday. The stock has a market cap of $2.90 billion, a P/E ratio of -4.96 and a beta of 1.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The company has a fifty day moving average price of $17.89 and a two-hundred day moving average price of $18.50. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.02). As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -2.94 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the stock. Morgan Stanley cut their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating for the company in a research note on Monday, March 2nd. JPMorgan Chase & Co. cut their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating for the company in a research note on Tuesday, January 20th. HC Wainwright cut their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 3rd. Chardan Capital restated a "buy" rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, Jefferies Financial Group restated a "buy" rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $35.14.
Read Our Latest Stock Analysis on DYN
Institutional Trading of Dyne Therapeutics
Hedge funds have recently modified their holdings of the stock. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics during the 1st quarter worth about $26,000. Chung Wu Investment Group LLC acquired a new stake in shares of Dyne Therapeutics during the 3rd quarter worth about $30,000. Strs Ohio acquired a new stake in shares of Dyne Therapeutics during the 4th quarter worth about $51,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the 4th quarter worth about $84,000. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock worth $95,000 after buying an additional 2,465 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
